Press release
Urticaria Pipeline: 20+ Innovators Driving the Next Wave of Advanced Treatment Options | DelveInsight
Urticaria Pipeline
DelveInsight's "Urticaria Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the urticaria market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.
For emerging urticaria drugs, the urticaria pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Urticaria Pipeline Report
• DelveInsight's urticaria pipeline analysis depicts a robust space with 20+ active players working to develop 25+ pipeline drugs for Urticaria treatment.
• The leading urticaria companies include Regeneron Pharmaceuticals, Taiho Pharmaceutical Co., Ltd, Allakos Inc, Yuhan Corporation, United BioPharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Kiniksa Pharmaceuticals, Ltd., Celldex Therapeutics, Longbio Pharma, Celltrion, Enanta Pharmaceuticals, and others are evaluating their lead assets to improve the urticaria treatment landscape.
• Key urticaria pipeline therapies in various stages of development include Dupilumab, TAS5315, AK006, YH35324, UB-221, TLL-018, KPL-716, AK002, CDX-0159, LP-003, CT-P39, Research programme: Chronic urticaria therapeutics, and others.
• In March 2025, Celltrion announced that the FDA approved OMLYCLO® (omalizumab-igec) as the first interchangeable biosimilar to XOLAIR® (omalizumab) for treating moderate to severe asthma, CRSwNP, IgE-mediated food allergies, and CSU.
• In November 2024, the FDA accepted for review the resubmission of the supplemental biologics license application (sBLA) for DUPIXENT (dupilumab) to treat adults and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 antihistamine treatment.
• In Sept 2024, Sanofi announced that Dupixent (dupilumab) met key endpoints in the LIBERTY-CUPID Study C Phase 3 trial for biologic-naïve chronic spontaneous urticaria (CSU) patients on antihistamines. This confirms findings from Study A, which led to Dupixent's approval in Japan for CSU earlier this year.
Request a sample and discover the recent breakthroughs happening in the urticaria pipeline landscape @ https://www.delveinsight.com/report-store/urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Urticaria Overview
Urticaria, commonly referred to as hives, is a skin condition marked by the sudden emergence of raised, itchy welts (also known as wheals) on the skin. These welts can range in size from small spots to large patches and may appear anywhere on the body. Affecting up to 20% of individuals at some point in their lives, urticaria is a relatively common condition. It can be classified as acute, lasting less than six weeks, or chronic, persisting for six weeks or longer.
Allergic reactions often trigger acute urticaria, while chronic forms are more complex and difficult to diagnose and manage due to their long-term and sometimes idiopathic nature. The hallmark symptom is the appearance of red, pink, or flesh-toned welts, frequently surrounded by a red halo. These lesions can shift location-disappearing in one area and reappearing in another within hours-and may vary significantly in shape and size.
Itching is the most common complaint, often accompanied by a burning or stinging sensation. In more severe cases, urticaria may lead to angioedema-deeper swelling beneath the skin-particularly around sensitive areas such as the eyes, lips, or genitals. When accompanied by symptoms like difficulty breathing or swallowing, the condition becomes a medical emergency requiring prompt intervention.
Find out more about urticaria medication @ https://www.delveinsight.com/report-store/urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Urticaria Treatment Analysis: Drug Profile
Dupilumab: Regeneron Pharmaceuticals
Dupilumab (Dupixent), developed by Regeneron using its VelocImmune® technology in collaboration with Sanofi, is a fully human monoclonal antibody that blocks IL-4 and IL-13 signaling-key drivers of type 2 inflammation. It is approved globally for several inflammatory conditions including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), and prurigo nodularis. With over 750,000 patients treated worldwide, Dupilumab is now in Phase III development for chronic urticaria.
TAS5315: Taiho Pharmaceutical Co., Ltd
TAS5315 is an oral BTK inhibitor under development by Taiho Pharmaceutical for multiple inflammatory conditions, including rheumatoid arthritis and chronic spontaneous urticaria. It is currently being evaluated in Phase II clinical trials for urticaria.
Key Urticaria Therapies and Companies
• Dupilumab: Regeneron Pharmaceuticals
• TAS5315: Taiho Pharmaceutical Co., Ltd
• AK006: Allakos Inc.
• Remibrutinib (LOU064): Novartis Pharmaceuticals
• DUPIXENT (dupilumab): Sanofi/Regeneron
• FASENRA (benralizumab): AstraZeneca/Kyowa Hakko Kirin
• Lirentelimab (AK002): Allakos/BioWa
• Rilzabrutinib (SAR444671): Sanofi
• Barzolvolimab (CDX-0159): Celldex Therapeutics
• TAS5315: Taiho Pharmaceutical
Learn more about the novel and emerging urticaria pipeline therapies @ https://www.delveinsight.com/report-store/urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Urticaria Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Scope of the Urticaria Pipeline Report
• Coverage: Global
• Key Urticaria Companies: Regeneron Pharmaceuticals, Taiho Pharmaceutical Co., Ltd, Allakos Inc, Yuhan Corporation, United BioPharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Kiniksa Pharmaceuticals, Ltd., Celldex Therapeutics, Longbio Pharma, Celltrion, Enanta Pharmaceuticals, and others.
• Key Urticaria Pipeline Therapies: Dupilumab, TAS5315, AK006, YH35324, UB-221, TLL-018, KPL-716, AK002, CDX-0159, LP-003, CT-P39, Research programme: Chronic urticaria therapeutics, and others.
Dive deep into rich insights for drugs used for urticaria treatment; visit @ https://www.delveinsight.com/report-store/urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Urticaria Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Urticaria Pipeline Therapeutics
6. Urticaria Pipeline: Late-Stage Products (Phase III)
7. Urticaria Pipeline: Mid-Stage Products (Phase II)
8. Urticaria Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. Through our subscription-based platform, PharmDelve, you can get hassle-free access to all the healthcare and pharmaceutical market research reports.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Urticaria Pipeline: 20+ Innovators Driving the Next Wave of Advanced Treatment Options | DelveInsight here
News-ID: 3974665 • Views: …
More Releases from DelveInsight
Breast Implants Market to Grow at a CAGR of 7.00% Through 2032 - Insights, Compe …
The breast implants market is experiencing steady growth, driven by increasing demand for cosmetic and reconstructive surgeries, rising awareness about aesthetic procedures, and advancements in implant technologies. Innovations such as textured and anatomically shaped implants, along with minimally invasive surgical techniques, are enhancing patient outcomes and satisfaction. Growing acceptance of breast augmentation in emerging markets is also fueling market expansion.
DelveInsight's Breast Implants Market Insights report delivers comprehensive market analysis, competitive…
Rehabilitation Equipment Market to Grow at a CAGR of 5.1% Through 2032 - Insight …
The rehabilitation equipment market is witnessing steady expansion, driven by the aging global population, rising prevalence of chronic and disabling conditions, and increasing demand for personalized physical therapy solutions. Technological advancements, including robotic-assisted rehabilitation and smart therapy devices, are enhancing recovery outcomes and improving patient independence across hospital, outpatient, and home-care settings.
DelveInsight's Rehabilitation Equipment Market Insights report offers an in-depth analysis of the market landscape, growth drivers and barriers, evolving…
Radiofrequency Ablation Devices Market to Grow at a CAGR of 9.37% Through 2032 - …
The radiofrequency ablation (RFA) devices market is expanding steadily due to the rising prevalence of chronic pain conditions, increasing cancer incidence, and growing preference for minimally invasive procedures. RFA devices are widely adopted in oncology, cardiology, and pain management for their effectiveness, reduced recovery times, and lower risk of complications.
DelveInsight's Radiofrequency Ablation Devices Market Insights report offers an in-depth analysis of the global market, key growth drivers, emerging trends, and…
DNA Sequencing Market to Grow at a CAGR of 18.02% Through 2032 - Insights, Compe …
The DNA sequencing market is witnessing strong momentum driven by the growing need for precision medicine, rapid advancements in next-generation sequencing (NGS) technologies, and increasing clinical applications across oncology, rare genetic disorders, and infectious disease management. As costs decline and data accuracy improves, DNA sequencing is becoming a cornerstone of both diagnostics and drug development.
DelveInsight's DNA Sequencing Market Insights report delivers detailed market analysis, key growth drivers, evolving trends, and…
More Releases for Pharma
Antiemetics Market Size 2022 Analysis by Top Key Players| Acacia Pharma Group Pl …
Antiemetics Market research added by the Absolute Markets Insights, offers a comprehensive analysis of growth trends prevailing in the global business domain. This report also provides definitive data concerning market, size, commercialization aspects and revenue forecast of the industry. In addition, the study explicitly highlights the competitive status of key players within the projection timeline while focusing on their portfolio and regional expansion endeavors.
Access the PDF sample of the report@…
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis.
Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382
The Indomethacin Global Market Research Report provides close monitoring…
Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 20 …
Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024.
Global Roxatidine Market overview:
Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the…
Indometacin Market Top Key Manufacturers Aidarex, Ratiopharm, Merck, Xinhua Phar …
The Global Indometacin Market is a nonsteroidal anti-inflammatory drug commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation. The demand for nonsteroidal anti-inflammatory drug has been increasing owing to the emergence of anti-inflammatory biologics that are more targeted. However, such as side effects of anti-inflammatory drugs and patent expiry issues may hamper the market growth in the review period.
For More Info, Get Sample Report…
Hydroxycarbamide Market Study Report 2019| Taj Pharma, Beijing Jialin Pharma, Qi …
Los Angeles, United State, June 11, 2019, - The global Hydroxycarbamide market is expected to surge at a steady CAGR in the coming years, states the latest QY Research report. The publication offers an insightful take on the historical data of the market and the milestones it has achieved. The report also includes an assessment of current market trends and dynamics, which helps in mapping the trajectory of the global Hydroxycarbamide…
TIGLUTIK Market 2019: Top Players are Sanofi, Mylan Pharma, Apotex, Glemark Gene …
TIGLUTIK Market 2019 Report analyses the industry status, size, share, trends, growth opportunity, competition landscape and forecast to 2025. This report also provides data on patterns, improvements, target business sectors, limits and advancements. Furthermore, this research report categorizes the market by companies, region, type and end-use industry.
Get Sample Copy of this Report@ https://www.researchreportsworld.com/enquiry/request-sample/13709986
Global TIGLUTIK market 2019 research provides a basic overview of the industry including definitions, classifications, applications…
